A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

NCT02440685 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

51

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Lymphoma, Large B-Cell, Diffuse
Lymphoma, Mantle-Cell
Lymphoma, Follicular
Cancer
Neoplasm
Tumor
Lymphoma, Malignant
Lymphoma, B-cell
Lymphoma, Non-Hodgkin
B-Cell Chronic Lymphocytic Leukemia
B-Cell Leukemia, Chronic
B-Lymphocytic Leukemia, Chronic
Chronic Lymphocytic Leukemia
Leukemia, Lymphocytic, Chronic
Leukemia, Lymphocytic, Chronic, B Cell
Myelofibrosis
Chronic Idiopathic Myelofibrosis
Idiopathic Myelofibrosis
Lymphoma, T Cell, Peripheral
Peripheral T-Cell Lymphoma
T-Cell Lymphoma, Peripheral

Interventions

DRUG: ASN002 Dose Escalation
DRUG: ASN002 RD

Sponsor

Asana BioSciences